Farxiga Patient Assistance Program: Eligibility and How to Apply

Farxiga, AstraZeneca’s SGLT2 inhibitor for type 2 diabetes, heart failure, and chronic kidney disease, has long carried a list price north of $600 for a 30-day supply. For an uninsured patient prescribed Farxiga long term, that is more than $7,000 a year, which is why programs like the Farxiga patient assistance program exist. Historically run through AstraZeneca’s AZ&Me Prescription Savings Program, the Farxiga patient assistance program has delivered Farxiga at no cost to qualifying Americans. Our healthcare costs guide covers how programs like this fit into the broader savings landscape.

This article is independent educational information, not medical or financial advice. FMHC is not affiliated with, endorsed by, or sponsored by AstraZeneca, and we do not administer AZ&Me. Program rules, prices, and drug availability change frequently — verify every detail directly with the source before you rely on it, and never start, stop, or change a prescription medication without talking to your prescriber.

Important 2026 Update: New Farxiga Enrollments Are Closed

Program terms can change without much notice, and Farxiga is a live example. According to AstraZeneca’s AZ&Me program, AZ&Me stopped accepting new patient-assistance enrollments for Farxiga (dapagliflozin) — and for Xigduo XR (dapagliflozin/metformin extended-release) — effective May 1, 2026. In practice, that means a newly prescribed, uninsured patient generally can no longer sign up to receive free Farxiga through AZ&Me the way they could in prior years.

If you were already enrolled before that date, your situation may differ — confirm your current status, refill timing, and renewal directly with AZ&Me at 1-800-AZandMe (1-800-292-6363). And because manufacturers periodically reopen, pause, or restructure these programs, it is always worth re-checking the official page rather than assuming the door is permanently closed. The rest of this guide explains how the program has worked (useful context and history) and, most importantly, the savings routes that remain open for dapagliflozin.

What the Farxiga Patient Assistance Program Provided

AstraZeneca operates AZ&Me, a patient assistance program that has shipped free AstraZeneca medications to eligible uninsured and Medicare Part D patients who cannot otherwise afford them. Farxiga (dapagliflozin) was one of the medications covered through AZ&Me, alongside products such as Brilinta, Symbicort, and several others. Approved patients received their medication at no cost, typically in multi-month shipments, with enrollment renewable periodically — the model that is now closed to new Farxiga applicants as of May 1, 2026.

The program is distinct from AstraZeneca’s Farxiga savings card, which is a commercial copay coupon aimed at privately insured patients. The savings card reduces your copay for covered fills but only if you have commercial (private) insurance. The Farxiga patient assistance program, by contrast, was designed for people who could not afford Farxiga at all because they had no insurance or because their Medicare plan left them with heavy out-of-pocket exposure.

Who AZ&Me Is Designed to Help

AZ&Me broadly serves two groups: U.S. residents who have no health insurance, and people covered under Medicare who still cannot afford their AstraZeneca medicines. Income eligibility for uninsured applicants has historically been set around 400% of the Federal Poverty Level, with a separate pathway and calculation for Medicare patients that also considers annual out-of-pocket drug spending. Exact thresholds are adjusted over time and differ for Alaska and Hawaii, so treat any specific dollar figure as an estimate and verify the current income limits with AZ&Me before applying for any covered medication.

In general, to be considered you must be a U.S. resident with a valid prescription written by a licensed U.S. prescriber, and you must not have other prescription coverage that pays for the medication. Patients enrolled in Medicaid are typically directed to Medicaid rather than AZ&Me. Medicare Part D patients can sometimes apply if they are not enrolled in full Extra Help. Commercially insured patients are steered to the manufacturer’s savings card instead.

How the AZ&Me Application Has Worked

For medications AZ&Me still accepts, the application is prescriber-directed. You start at the official AZ&Me site or call 1-800-AZandMe (1-800-292-6363) to request an enrollment form. The form has patient, prescriber, and attestation sections. You complete the patient section with household size, income, insurance status, and contact information.

Your prescribing clinician completes the prescriber section with your diagnosis, dose, and treatment plan, then signs — both signatures are required. You attach proof of household income, usually your most recent IRS Form 1040 or recent pay stubs or Social Security benefit letters. AZ&Me reviews the application and notifies you and your prescriber of the decision. Processing has generally taken a few weeks, and approved medication has shipped to the prescriber’s office or a designated pharmacy. Because Farxiga specifically is now closed to new enrollment, this pathway applies to other AZ&Me-covered medicines rather than to a new Farxiga request.

Savings Routes That Remain Open for Dapagliflozin

If AZ&Me is no longer an option for your Farxiga, several alternatives are worth pricing out with your prescriber and pharmacist:

• Farxiga savings card (commercial insurance only). If you have private/commercial insurance, the Farxiga savings card from farxiga.com can lower your copay, subject to per-fill and annual limits. It does not require income verification but is not available to people with Medicare, Medicaid, or other government insurance, and it is not insurance.
• Generic dapagliflozin. As generic dapagliflozin becomes available in the U.S. market, the cash price can drop substantially versus brand Farxiga. Ask your pharmacist whether a generic is stocked and whether your prescriber can write for it — availability and pricing are changing, so verify current options locally.
• Nonprofit copay foundations. Groups such as the PAN Foundation and HealthWell Foundation periodically open diabetes, heart failure, and chronic kidney disease funds that can help with copays. Funds open and close based on donations, so check availability when you need it.
• Cash-price discount tools. Discount programs and pharmacy shopping (comparing multiple pharmacies) can meaningfully cut the out-of-pocket cost of a brand or generic fill, especially for the uninsured.
• Medicare help. Medicare Part D patients facing high out-of-pocket costs should check eligibility for the Medicare Extra Help program through Social Security and can opt into the Medicare Prescription Payment Plan (M3P), which lets you spread Part D out-of-pocket costs over the year up to the 2026 annual cap of $2,100.

Our NovoCare PAP guide and Novartis PAP guide describe parallel programs from other manufacturers for people comparing diabetes and specialty-drug options.

Patient Assistance vs the Savings Card: Know the Difference

These two things are frequently confused. A manufacturer patient assistance program (like AZ&Me) provides free medication to people who cannot afford it on any insurance — it is income-based and prescriber-directed. A savings card reduces the copay on an insured fill for people who already have commercial coverage — it is not income-tested but excludes government-insured patients. They are not interchangeable. If you are uninsured or on Medicare with high out-of-pocket exposure, the assistance/foundation route (where available) is the relevant one; if you have commercial insurance, the savings card is usually faster.

Patients who recently lost employer coverage and have not yet enrolled in marketplace insurance sometimes used AZ&Me as a bridge in the past. With new Farxiga enrollment now closed, a better bridge today may be a generic dapagliflozin fill at a discounted cash price, a copay foundation grant, or enrolling in a marketplace plan through healthcare.gov during a special enrollment period.

Frequently Asked Questions

Can I still get free Farxiga through AZ&Me in 2026?

New Farxiga (and Xigduo XR) enrollments through AZ&Me closed effective May 1, 2026, so a newly prescribed patient generally cannot sign up for free Farxiga through the program now. If you were already enrolled, confirm your status directly with AZ&Me at 1-800-292-6363. Programs can change, so re-check the official page rather than assuming.

What should I do instead if I can’t afford Farxiga?

Talk to your prescriber and pharmacist about generic dapagliflozin as it becomes available, the commercial savings card (if you have private insurance), nonprofit copay foundations, cash-price discounts, and — for Medicare — Extra Help and the Medicare Prescription Payment Plan. Do not skip or ration a prescribed medication on your own; ask your care team for the most affordable equivalent.

Is the Farxiga savings card the same as patient assistance?

No. The savings card is a commercial copay coupon for people with private insurance and is not available to Medicare, Medicaid, or other government-insured patients. Patient assistance (AZ&Me) is an income-based program for people who cannot afford the medicine at all. They serve different situations.

Does AZ&Me still help with other AstraZeneca medicines?

AZ&Me continues to support eligible uninsured and Medicare patients for many AstraZeneca products, even though new Farxiga and Xigduo XR enrollment is closed. Check the current covered-medication list and eligibility on the official AZ&Me site or by phone.

How much income disqualifies me from AZ&Me?

Income limits for uninsured applicants have historically been set around 400% of the Federal Poverty Level, with a different calculation for Medicare patients. The exact thresholds change annually and differ for Alaska and Hawaii, so verify the current numbers directly with AZ&Me rather than relying on an estimate.

The Bottom Line

The Farxiga patient assistance program, run through AstraZeneca’s AZ&Me program, historically provided free Farxiga to qualifying uninsured and eligible Medicare patients — but new Farxiga (and Xigduo XR) enrollments closed effective May 1, 2026. If you were already enrolled, confirm your status at 1-800-AZandMe (1-800-292-6363). If you are newly prescribed and struggling with cost, work with your prescriber and pharmacist on the routes that remain: the commercial savings card (private insurance only), generic dapagliflozin as it becomes available, nonprofit copay foundations, cash-price discounts, and Medicare’s Extra Help and 2026 Prescription Payment Plan. Because these programs and prices shift often, verify current terms directly with each source.

Sources

• AstraZeneca AZ&Me Prescription Savings Program (azandmeapp.com) — eligibility for uninsured and Medicare patients, phone 1-800-AZandMe (1-800-292-6363), and the May 1, 2026 close of new Farxiga and Xigduo XR enrollments
• Farxiga.com / AstraZeneca — Farxiga Savings Card terms (commercial insurance only; government-insured patients excluded)
• MedlinePlus (NIH) — dapagliflozin (Farxiga) uses for type 2 diabetes, heart failure, and chronic kidney disease, and its SGLT2-inhibitor drug class
• HHS — Federal Poverty Level guidelines used for income thresholds
• CMS / Medicare.gov — 2026 Medicare Part D out-of-pocket cap ($2,100), the Medicare Prescription Payment Plan (M3P), and Extra Help
• Nonprofit copay foundations — PAN Foundation and HealthWell Foundation (diabetes and chronic kidney disease assistance funds)